HONG KONG – Another China-based company has filed for a $100 million IPO on Nasdaq, testing what has been a friendly environment for biotech. Hutchison China Meditech Ltd. hasn’t decided on the timeline of the listing, nor the number and price of shares.

HONG KONG – After being granted phase II trial approval in Sierra Leone last Saturday for its novel Ebola vaccine, Tianjin Cansino Biotechnology Inc. became the first Chinese vaccine company with a self-developed vaccine approved for clinical trials in a foreign country.

HONG KONG – Carsgen Therapeutics Ltd. and Shanghai Cancer Institute entered a five-year research and development agreement for Carsgen's chimeric antigen receptors T-cell (CAR-T) cancer immunotherapeutic candidates. The partners will work together to discover and develop CAR-T candidates as well as next-generation CAR-T drug candidates.

HONG KONG – Carsgen Therapeutics Ltd. and Shanghai Cancer Institute entered a five-year research and development agreement for Carsgen's chimeric antigen receptors T-cell (CAR-T) cancer immunotherapeutic candidates.

HONG KONG – Genova Biotechnology Co. Ltd. is aiming to be the largest insulin maker in China, starting construction on a $1 billion manufacturing facility in Changzhou National Hi-tech District this month.

HONG KONG – Genova Biotechnology Co. Ltd. is aiming to be the largest insulin maker in China, and is starting construction on a $1 billion manufacturing facility in Changzhou National Hi-tech District this month.